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Inflammatory bowel disease (IBD), namely Crohn’s dis-
ease and ulcerative colitis, is a group of systemic con-
ditions with predominant intestinal inflammation1,2. 
Similar to other immune-mediated inflammatory dis-
eases (IMIDs), such as psoriasis and rheumatoid arthri-
tis, IBD can be associated with different comorbidities, 
including thrombosis3. Patients with IBD are known to 
carry an increased risk of developing both arterial and 
venous thrombosis4 (Fig. 1).
Patients with IBD have several factors that influence 
the pathophysiological mechanisms of venous throm-
boembolism (VTE) encompassed in the well-known 
Virchow’s triad: stasis of venous flow (for example, bed 
rest), endothelial injury (for example, surgery or trauma) 
and hypercoagulability (for example, inflammation 
through several mechanisms, sepsis and antiphospho-
lipid antibodies)5–7. Inflammation plays an important 
role in the development of accelerated atherosclerotic 
disease, which can lead to arterial thrombotic events8 
(Fig. 2). This feature has been shown across the spectrum 
of IMIDs, as well as in the general population9,10.
Anti-inflammatory drugs used for the treatment of 
IBD can reduce inflammation and potentially the risk 
of thrombosis. Whether JAK inhibitors might have an 
intrinsic pro-thrombotic effect is the subject of intensive 
research11.
The aim of this Evidence-Based Guideline is to 
summarize available evidence and to provide practical 
recommendations agreed by consensus regarding epi-
demiological aspects, prevention, and drug-related risk 
of venous and arterial thrombotic events in patients 
with IBD.
Methods
A literature search was conducted by P.A.O. and L.P.-B. 
to evaluate the current knowledge on the epidemiology 
of thrombotic events in IBD, and how available IBD 
therapies impact the risk of these events. Published 
International consensus on the 
prevention of venous and arterial 
thrombotic events in patients with 
inflammatory bowel disease
Pablo A. Olivera1, Stephane Zuily  2,3, Paulo G. Kotze  4, Veronique Regnault3,  
Sameer Al Awadhi5, Peter Bossuyt  6, Richard B. Gearry7, Subrata Ghosh  8, 
Taku Kobayashi  9, Patrick Lacolley3, Edouard Louis10, Fernando Magro11,  
Siew C. Ng  12, Alfredo Papa  13,14, Tim Raine  15, Fabio V. Teixeira16, David T. Rubin  17, 
Silvio Danese  18,19 and Laurent Peyrin-Biroulet  20 ✉
Abstract | Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic  
events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based 
Guideline were to summarize available evidence and to provide practical recommendations 
regarding epidemiological aspects, prevention and drug-related risks of venous and arterial 
thrombotic events in patients with IBD. A virtual meeting took place in May 2020 involving 
14 international IBD experts and 3 thrombosis experts from 12 countries. Proposed statements were 
voted upon in an anonymous manner. Agreement was defined as at least 75% of participants voting 
as ‘fully agree’ or ‘mostly agree’ with each statement. For each statement, the level of evidence  
was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. 
Consensus was reached for 19 statements. Patients with IBD harbour an increased risk of venous 
and arterial thrombotic events. Thromboprophylaxis is indicated during hospitalization of any cause 
in patients with IBD. Disease activity is a modifiable risk factor in patients with IBD, and physicians 
should aim to achieve deep remission to reduce the risk. Exposure to steroids should be limited. 






NATure revIewS | GASTRoEnTERoloGy & HEPAToloGy
EVIDENCE-BASED
guidelines
  volume 18 | December 2021 | 857
0123456789();: 
studies were identified using MEDLINE and EMBASE 
from inception until 20 May 2020. Databases of major 
congresses (European Crohn’s and Colitis Organization, 
Digestive Disease Week, and United European 
Gastroenterology Week) in the period 2012–2019 were 
also reviewed manually. Search strategies are provided 
in Supplementary Table 1. Proposed statements were 
prepared by P.A.O. and L.P.-B. prior to the meeting 
and presented according to two predefined categories: 
epidemiology of thrombosis in IBD, and prevention of 
thrombosis in IBD, including drug-related. A consensus 
meeting was originally planned to take place in Lisbon, 
Portugal, on 27 May 2020. Owing to the COVID-19 pan-
demic, the consensus meeting took place virtually via the 
Zoom platform on the same day instead.
The objectives of the consensus were: to define the 
risk of both venous and arterial thrombotic events 
in patients with IBD; to give recommendations on 
reducing the risk of thrombotic events; to define the 
risk of drug-related thrombosis in patients with IBD; 
and to give recommendations on reducing the risk of 
drug-related thrombosis. Attendees of the virtual con-
sensus included 14 IBD experts, three experts in clinical 
and basic aspects of thrombosis and one fellow, from 
14 countries. During the meeting, the results of the liter-
ature review were presented, followed by presentation of 
the proposed statements. Each proposed statement was 
voted upon in an anonymous manner using the voting 
system of the Zoom platform. Agreement was defined 
as at least 75% of participants voting as ‘fully agree’ or 
‘mostly agree’ with each proposed statement. If a 75% 
agreement was not achieved, further discussion ensued, 
which might have included amendment of voting state-
ments when required, followed by a second round of 
voting using the same approach as before if the state-
ment remained controversial. If agreement could not 
be reached after two rounds of voting, then the state-
ment was definitely excluded. For each statement, the 
level of evidence was graded according to the Scottish 
Intercollegiate Guidelines Network (SIGN) grading sys-
tem (Supplementary Table 2). The SIGN grading system 
is a widely used critical appraisal and evidence hier-
archy that has the important advantage of being simple 
and easy to use12. The methodology is based on a set 
of variables that recognize key factors, especially bias 
and confounding factors, that can influence the quality 
of a study. The final grade of recommendation (A, B, 
C or D) is based on the lowest level of evidence appli-
cable to a key outcome12. Consensus was reached for 
19 statements (Box 1), and 6 statements were excluded 
(Supplementary Table 3).
Risk of venous and arterial thrombotic events  
in IBD
Statement 1: IBD is associated with a twofold greater risk 
of VTE events. 
•	Consensus reached for 94%. Vote: fully agree 65%, 
mostly agree 29%.
•	 Evidence level 2+.
Several population-based IBD cohort studies have 
investigated the risk of VTE events13–17. A meta-analysis 
by Yuhara et al. summarizing data from 11 observational 
studies, found a relative risk (RR) of 2.20 (95% CI 1.83–
2.65) for deep vein thrombosis (DVT) and pulmonary 
embolism (PE) in patients with IBD compared with 
individuals without IBD18. However, significant hetero-
geneity between studies was detected. An increased 
risk was seen in patients with ulcerative colitis (RR 2.57, 
95% CI 2.02–3.28) and Crohn’s disease (RR 2.12, 95% 
CI 1.40–3.20)18. A separate meta-analysis by Fumery 
et al. that included ten studies involving both hospital-
ized and ambulatory patients, found an increased risk 
of VTE in patients with IBD, with a RR of 1.96 (95% CI 
1.67–2.30)19. The risk in patients with Crohn’s disease 
and ulcerative colitis did not differ, except when con-
sidering only studies evaluating hospitalized patients, 
in whom the increased risk of VTE was greater in those 
with ulcerative colitis (P = 0.0029)19.
The risk of VTE can be further modulated by the 
presence of other factors frequently seen in patients 
with IBD, such as surgery, pregnancy, disease activ-
ity and hospitalizations (see Statement 3 and TaBle 1). 
Additionally, other risk factors should also be taken into 
account (see Statement 2).
Statement 2: Patients with IBD should be screened for 
VTE risk factors. 
•	Consensus reached for 100%. Vote: fully agree 75%, 
mostly agree 25%.
•	 Evidence level 4.
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Several inherited and acquired factors are related 
with an increased risk of VTE. Patients with IBD should 
be thoroughly investigated for additional risk factors of 
thrombosis, as the presence of multiple factors might 
increase the risk further20. The overall risk assessment 
should be taken into account when making clinical 
decisions.
VTE events are categorized as provoked and unpro-
voked, depending on the presence of an acquired risk 
factor21 (Box 2). Additionally, these factors can be tran-
sient (for example, surgery) or persistent (for example, 
antiphospholipid syndrome), which could have poten-
tial implications on prognosis and treatment decisions21. 
When the VTE event is provoked by a transient major 
risk factor, the risk of recurrent VTE is low after stop-
ping therapy when the risk factor has disappeared, and 
long-time anticoagulation is not warranted in general22. 
In case of a persistent major risk factor, such as active 
cancer, the risk of recurrence is high as long as the 
factor is present and, therefore, anticoagulation should 
be continued.
Patients with IBD do not seem to be at an increased 
risk of inherited thrombophilia23,24. Several studies have 
shown that the prevalence of genetic mutations associ-
ated with an increased risk of VTE (for example, factor V 
Leiden polymorphism25,26, G20210A mutation in the 
prothrombin gene27, and homozygous C677T mutation 
in the MTHFR gene24,28–30) are similar in patients with 
and without IBD, and also when comparing patients 
with IBD with or without VTE23,31–40. Consequently, 
patients with IBD should not be routinely screened for 
genetic or acquired laboratory abnormalities related to 
thrombophilia, with the exception of the occurrence of 
an unprovoked VTE event in the absence of risk factors 
(Box 2) and intestinal inflammation (that is, patient in 
deep remission).
Acquired risk factors for VTE include a history of a 
VTE event, older age (>65 years), obesity, ongoing malig-
nancy and recent major surgery (higher after ortho-
paedic surgery), as well as other medical conditions41 
(Box 2). These clinical risk factors should be assessed in 
all patients with IBD, according to existing guidelines at 
baseline42. Many of these risk factors are transient, and 
need a continuous re-evaluation, especially when the 
clinical condition changes (such as flare, hospitalization, 
surgery, complication, discharge and so on). Different 
thrombosis risk assessment models (RAMs) have been 
developed for specific clinical scenarios43. Notably, 
most of these RAMs do not include IBD as a risk factor. 
A widely used model is the modified Caprini RAM for 
use in patients undergoing surgery44. For non-surgical 
inpatients who are acutely ill, several RAMs have been 
developed (such as the Padua prediction score45, the 
IMPROVE risk score46 and the GENEVA risk score47), 
although their performance is variable. Another example 
is the Khorona score, which predicts the risk of VTE in 
ambulatory patients with cancer48. Unfortunately, there 
is a paucity of specific and validated screening tools for 
the assessment of the overall risk of VTE in patients with 
IBD. Two RAMs were developed for use in the IBD pop-
ulation, one to predict the risk of VTE after abdominal 
surgery49, and the other to predict the risk of VTE after 
discharge50 (see Statement 4), but neither has been val-
idated. Development of validated tools is imperative to 
enable correct assessment of the risk of thrombosis and 
to adequately implement tailored prophylactic measures 
in different clinical scenarios.
Statement 3: The risk of VTE in patients with IBD is 
related to disease activity and it is further increased 
during hospitalization. 
•	Consensus reached for 100%. Vote: fully agree 82%, 
mostly agree 18%.
•	 Evidence level 2−.
Disease activity has an important role in the risk of 
VTE in patients with IBD. Additionally, this risk seems 
to be modulated by the setting of the IBD flare (hos-
pitalization, early discharge or ambulatory (TaBle 2, 
see Statements 4 and 5)).
In a large cohort study from the UK (comparing 13,756 
patients with IBD and 71,672 matched controls), Grainge 
et al. found that patients with IBD have a higher risk of 
VTE than controls (up to five controls matched for age, sex 
and general practice were selected for every patient with 
IBD from the General Practice Research Database) with a 
hazard ratio of 3.4 (95% CI 2.7–4.3)51. During periods of 
active flare, the risk was more prominent (HR 8.4, 95% CI 
5.5–12.8) than during periods of remission (HR 2.1, 95% 
CI 1.6–2.9) compared with that in controls. The incidence 
of VTE in patients with active IBD flare during hospital-
ization remained the highest. However, the relative risk 
during flare in the ambulatory setting was higher (HR 
15.8, 95% CI 9.8–25.5; P < 0.0001) than during hospital-
ization (HR 3.2, 95% CI 1.7–6.3) compared with that in 
the general population51. Importantly, the definition of 
active disease in this study was corticosteroid use, so this 
study could not adequately separate the effects of active 
inflammation from the effects of the corticosteroids on 
VTE. Additionally, corticosteroids are usually indicated 
for the treatment of moderate-to-severe IBD disease 
activity. Hence, the influence of mild IBD compared with 
true remission remains unclear.
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Fig. 1 | Arterial and venous sites of thrombosis in patients with IBD. Common sites  
of arterial and venous thrombosis are shown in bold, atypical sites are not bolded. 
IBD, inflammatory bowel disease.
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In a single-centre cohort study that included 
84 patients with IBD, 71% of patients with IBD with a 
history of thrombotic events had active disease at the 
time of the event52. A population-based cohort study, 
which included 1,046,754 women with 1,978,701 deliv-
eries, showed that disease flare-up during pregnancy was 
associated with a statistically significantly increased risk 
of VTE (RR 2.64, 95% CI 1.69–4.14) when compared 
with the risk in pregnant patients with IBD without 
flare-ups during pregnancy53.
Nguyen and Sam found higher rates of VTE in hos-
pitalized patients with IBD than in hospitalized patients 
without IBD. In this study, VTE was associated with 
longer hospital stays, higher hospitalization-related costs 
and, importantly, a greater mortality among patients 
with IBD (adjusted OR 2.50, 95% CI 1.83–3.43)15. In a 
population-based study from Korea, Kim et al. con-
cluded that the risk of VTE was the highest during 
IBD-related surgery and hospitalization due to flare-up54. 
Importantly, the risk of VTE also remained elevated dur-
ing hospitalization not due to flare up in another study55, 
highlighting the need for thromboprophylaxis in patients 
hospitalized for any cause (see Statement 4). In a retro-
spective multicentre cohort study that included 11,028 
patients with IBD, of whom 2,788 had had at least one 
IBD-related hospitalization, Ananthakrishnan et al.56 
found that IBD-related hospitalization was the strongest 
risk factor for VTE (OR 1.72, 95% CI 1.39–2.12).
Statement 4: Thromboprophylaxis should be given to 
patients with IBD during hospitalization of any cause. 
Low molecular weight heparin or fondaparinux is rec-
ommended over low-dose unfractionated heparin. 
Prophylaxis should be maintained during the inpatient 
period. Extended duration of prophylaxis after discharge 
should be considered only in patients with strong risk 
factors for VTE. 
•	Consensus reached for 89%. Vote: fully agree 18%, 
mostly agree 71%.
•	 Evidence level 2+.
In accordance with current guidelines on the pre-
vention of VTE during hospitalization, patients with 
IBD should receive pharmacological thromboprophy-
laxis during the inpatient period regardless of the 
cause of hospitalization32,42,57. In the study by Grainge 
et al., hospitalized patients with IBD had higher risk 
of VTE than patients without IBD, even during peri-
ods of remission (HR 1.7, 95% CI 1.1–2.9; P = 0.03)51, 






























































Fig. 2 | Pathophysiology of thrombosis in IBD. This figure depicts the alterations involved in the increased risk of 
thrombosis in patients with inflammatory bowel disease (IBD): platelet alterations leading to activation; procoagulant 
alterations leading to activation of the coagulation cascade; dysregulated fibrinolysis. ADAMTS13, a disintegrin and 
metalloproteinase with a thrombospondin type 1 motif, member 13; GPIIb/GPIIIA, glycoprotein IIb/IIIa; PAI1, plasminogen 
activator inhibitor 1; PAR, protease-activated receptor; PF4, platelet factor 4; TAFI, thrombin-activatable fibrinolysis 
inhibitor; TF, tissue factor; TFPI, tissue factor pathway inhibitor; tPA, tissue plasminogen activator; uPA, urokinase-type 
plasminogen activator; VWF, von Willebrand factor. Elements of Fig. 2 adapted with permission from reF.7, Elsevier.
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thromboprophylaxis during hospitalization of any 
cause. In another study, thromboprophylaxis during 
the index hospitalization was associated with a signif-
icantly lower risk of VTE after discharge (HR 0.46, 95% 
CI 0.22–0.97)56.
Guidelines recommend pharmacological over 
mechanical thromboprophylaxis, given that the for-
mer may be more effective in the prevention of PE and 
symptomatic VTE32,42,58,59. The preferred methods of 
prophyl axis are low molecular weight heparin (LMWH) 
or fondaparinux over unfractionated heparin (UFH)42. 
LMWH was associated with lower rates of PE, symp-
tomatic DVT, major bleeding and heparin-induced 
thrombo cytopenia than UFH42,60. Additionally, 
fondaparinux might reduce mortality, PE, distal DVT 
and major bleeding, when indirectly compared with 
UFH and LMWH42. A combined analysis of three rand-
omized controlled trials (RCTs) that evaluated direct oral 
anticoagulants (DOACs) against LMWH for primary 
prevention of VTE in medical inpatients61–63 showed 
that DOACs are not associated with a clinical benefit 
compared with LMWH and led to an increased risk of 
major bleeding42. Thus, DOACs are not recommended 
as primary prophylaxis of VTE during hospitalization in 
all patients, including those with IBD.
An extended duration of thromboprophylaxis 
beyond hospital discharge is not routinely recommended 
in patients with IBD. However, surgical and orthopaedic 
research have shown that the risk of VTE can remain ele-
vated even after hospital discharge64–66, and a subgroup 
of patients might benefit from an extended duration of 
VTE prophylaxis67. In a retrospective cohort study that 
analysed 872,122 index admissions of patients with 
IBD, 91% of readmissions due to VTE occurred in the 
60 days following discharge, with the risk being highest 
in the first 10 days after discharge68. Factors associated 
with readmission with VTE included older age, pres-
ence of comorbidities, history of VTE, having a flexi-
ble sigmoidoscopy or colonoscopy on index admission, 
Clostridioides difficile infection, discharge to a nursing or 
intermediate facility and discharge home with services68. 
In a large retrospective cohort study that included 24,182 
patients, 30-day total and post-discharge rates of VTE 
were 2.5% and 1%, respectively, following elective 
abdominopelvic bowel surgery in patients with IBD49. 
Factors associated with increased rates of post-discharge 
VTE were preoperative transfusion, steroid use, pelvic 
and enterocutaneous fistula surgery, and longer opera-
tive time49. Additionally, a study by Chu et al. also found 
that the risk of VTE remained elevated within 6 weeks of 
discharge in patients with IBD following major surgery69. 
The American Society of Colon and Rectal Surgeons 
clinical practice guidelines do recommend extended 
thromboprophylaxis in selected high-risk patients with 
IBD following abdominal surgery (weak recommenda-
tion, very low quality evidence)59. The cost-effectiveness 
of this strategy remains to be fully defined. A Canadian 
study showed that extended thromboprophylaxis 
(28-day course of enoxaparin) after colorectal sur-
gery due to malignancy or IBD had higher costs than 
standard management (inpatient administration only), 
but more quality-adjusted life-years (QALYs), and an 
incremental cost-effectiveness ratio70. However, in a 
study by Leeds et al., extended prophylaxis following 
surgery for Crohn’s disease was not cost-effective when 
the cumulative incidence of VTE after hospitalization 
remained <4.9%71.
Box 1 | Consensus statements
•	Statement 1: Inflammatory bowel disease (IbD) is associated with a twofold greater 
risk of venous thromboembolism (vTe) events (consensus reached for 94%). evidence 
level 2+.
•	Statement 2: Patients with IbD should be screened for vTe risk factors (consensus 
reached for 100%). evidence level 4.
•	Statement 3: The risk of vTe in patients with IbD is related to disease activity and it is 
further increased during hospitalization (consensus reached for 100%). evidence level 2−.
•	Statement 4: Thromboprophylaxis should be given to patients with IbD during 
hospitalization of any cause. low molecular weight heparin or fondaparinux is 
recommended over low-dose unfractionated heparin. Prophylaxis should be 
maintained during the inpatient period. extended duration of prophylaxis after 
discharge should be considered only in patients with strong risk factors for vTe 
(consensus reached for 89%). evidence level 2+.
•	Statement 5: Thromboprophylaxis should be considered in ambulatory patients  
with active IbD with known risk factors for vTe and maintained until the patient is  
in remission (consensus reached for 95%). evidence level 4.
•	Statement 6: Thromboprophylaxis does not increase the risk of further IbD-related 
gastrointestinal bleeding in patients with active disease (consensus reached for 
100%). evidence level 2+.
•	Statement 7: IbD is associated with a small but significant increased risk of 
arterial thrombotic events, especially in young patients with active disease 
(consensus reached for 100%). evidence level 2++.
•	Statement 8: The risk of cerebrovascular accidents and ischaemic heart disease 
seems to be increased in female patients with IbD, but not in male patients 
(consensus reached for 94%). evidence level 2++.
•	Statement 9: The risk of peripheral artery disease is modestly increased, especially in 
young patients with crohn’s disease (consensus reached for 87%). evidence level 2+.
•	Statement 10: The risk of mesenteric ischaemia is increased in patients with IbD, 
especially in young patients with ulcerative colitis (consensus reached for 93%). 
evidence level 2+.
•	Statement 11: control of disease activity is an important factor in reducing the risk  
of venous and arterial thrombotic events in patients with IbD (consensus reached  
for 93%). evidence level 4.
•	Statement 12: established cardiovascular disease risk factors should be actively 
investigated and controlled in patients with IbD (consensus reached for 100%). 
evidence level 4.
•	Statement 13: There is limited evidence regarding the effect on the risk of vTe  
of 5-aminosalicylic acid (5-ASA), thiopurines or methotrexate in patients with  
IbD (consensus reached for 100%). evidence level 3.
•	Statement 14: 5-ASA is associated with a reduced risk of ischaemic heart disease  
in patients with IbD, especially when given in the long term (consensus reached  
for 100%). evidence level 2−.
•	Statement 15: Steroids are associated with an increased risk of venous and arterial 
thrombotic events in patients with IbD (consensus reached for 100%). evidence level 2++.
•	Statement 16: Anti-TNF agents can be associated with a decreased risk of vTe in 
patients with IbD (consensus reached for 100%). evidence level 2+.
•	Statement 17: Anti-TNF agents can be associated with a reduced risk of arterial 
events in patients with IbD (consensus reached for 94%). evidence level 2+.
•	Statement 18: Tofacitinib can be associated with a dose-dependent increased risk of 
vTe in patients with rheumatoid arthritis with risk factors for vTe. According to available 
evidence, no increase in the risk of vTe has been observed in the overall ulcerative colitis 
population treated with tofacitinib (consensus reached for 100%). evidence level 1+.
•	Statement 19: Tofacitinib is not associated with an increased risk of major adverse 
cardiovascular events in patients with ulcerative colitis (consensus reached for 100%). 
evidence level 1−.
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Consequently, an extended duration of thrombo-
prophylaxis can be considered for an additional period 
of 2–8 weeks after hospital discharge in patients with 
a very high risk of VTE, and identification of these 
patients is of the utmost importance. In a single-centre 
retrospective study published in 2019, McCurdy et al. 
developed a risk model for VTE after discharge that 
included age >45 years, multiple admissions, intensive 
care unit admission, length of admission >7 days and 
presence of a central catheter; by limiting extended 
thromboprophylaxis to high-risk patients identified by 
the score, the authors concluded that treatment could be 
avoided in 92% of patients after discharge50. However, 
this RAM needs further validation, and until then phy-
sicians should rely on clinical gestalt to estimate the risk 
of VTE after hospital discharge.
Statement 5: Thromboprophylaxis should be considered 
in ambulatory patients with active IBD with known risk 
factors for VTE, and maintained until the patient is in 
remission. 
•	Consensus reached for 95%. Vote: fully agree 24%, 
mostly agree 71%.
•	 Evidence level 4.
Moderate to severe IBD activity is a known risk factor 
for VTE. Most IBD flares occur in an ambulatory setting 
but given that the thresholds for hospitalization due to 
IBD flare differ worldwide, the proportions of inpatients 
and outpatients with IBD having a VTE event can vary. 
Moderate to severe IBD should be considered as a risk 
factor for VTE in the presence of clinical signs of activity 
in addition to objective markers of inflammation (that 
is, elevated C-reactive protein (CRP) or calprotectin 
levels, or signs of moderate to severe inflammation in 
endoscopic or cross-sectional evaluations).
In the study by Grainge et al., the relative risk of VTE 
during a disease flare compared with that in the gen-
eral population was higher during ambulatory periods 
(HR 15.8, 95% CI 9.8–25.5) than during hospitalized 
periods (HR 3.2, 95% CI 1.7–6.3)51. An Austrian multi-
centre cohort study that included 2,784 patients with 
IBD (total observation time 24,778 person-years) found 
that most VTE events (77.8%) occurred in outpatients72. 
Additionally, 77.1% of VTE events were unprovoked by 
classic provoking risk factors, such as surgery, trauma 
or indwelling catheters, although almost two-thirds 
(60.9%) of the patients had active disease at the time of 
first VTE72. However, in the study by Grainge et al., the 
incidence of VTE during flares was much lower dur-
ing ambulatory periods than during hospitalized peri-
ods (6.4 per 1,000 person-years versus 37.5 per 1,000 
person-years)51. Given that the absolute risk of VTE 
remains low in outpatients with active IBD, the use of 
Table 1 | Risk of VTE in different clinical scenarios
Setting Findings Ref.
Hospitalization The incidence rate of VTE in patients with active IBD flare during 
hospitalization was the highest (37.5 per 1,000 patient-years)
The relative risk when compared with controls increased threefold  
(HR 3.2, 95% CI 1.7–6.3)
Grainge et al.51
Among hospitalized patients, those with ulcerative colitis (OR 1.85, 95% CI 
1.70–2.01) and those with Crohn’s disease (OR 1.48, 95% CI 1.35–1.62) had 
higher rates of VTE than patients without IBD
VTE was associated with longer hospital stays, higher 
hospitalization-related costs and higher mortality among patients with IBD 
(adjusted OR 2.50, 95% CI 1.83–3.43)
Nguyen and Sam15
IBD-related surgery (adjusted HR 40.81; 95% CI 10.16–163.92) and 
hospitalization due to flare-up (adjusted HR 19.36, 95% CI 9.59–39.07)  
were the highest risk factors for VTE
The risk of VTE also remained elevated in patients hospitalized without 
flare-up (adjusted HR 12.97 , 95% CI 8.68–19.39)
Kim et al.54
IBD-related hospitalization was the strongest risk factor for VTE (OR 1.72, 
95% CI 1.39–2.12)
Ananthakrishnan et al.56
Early discharge Thromboprophylaxis during the index hospitalization was associated with a 
significantly lower risk of post-hospitalization VTE (HR 0.46, 95% CI 0.22–0.97)
Ananthakrishnan et al.56
91% of readmissions due to VTE after an index IBD hospitalization occurred 
in the 60 days following discharge, with the risk being highest in the first 10 
days after discharge
Faye et al.68
30-day total and post-discharge rates of VTE were 2.5% and 1% following 
elective abdominopelvic bowel surgery in patients with IBD
Benlice et al.49
The risk of VTE remained elevated within 6 weeks of discharge in patients 
with IBD following major surgery
Chu et al.69
Ambulatory The relative risk during flare in the ambulatory setting was higher (HR 15.8, 
95% CI 9.8–25.5; P < 0.0001) than during hospitalizations (HR 3.2, 95% CI 
1.7–6.3), when compared with the risk in the general population
Grainge et al.51
Most VTE events (77.8%) occurred in outpatients Papay et al.72
IBD, inflammatory bowel disease; VTE, venous thromboembolism.
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thromboprophylaxis is not recommended in the absence 
of risk factors. In a Markov decision analysis, it was esti-
mated that thromboprophylaxis during ambulatory IBD 
flares was not cost-effective, with a number needed to 
treat to prevent one VTE event over a lifetime of 32.3 and 
a cost of US$1,267,450 for every QALY gained73.
On the other hand, outpatients with major risk fac-
tors or multiple risk factors in addition to a moderate to 
severe IBD flare might be at a particular high risk of VTE 
(Box 2) and could benefit from thromboprophylaxis until 
the transient provoking factor disappears (that is, patient 
achieves remission). This approach might be particularly 
relevant in patients with a history of VTE provoked by 
IBD flare who are no longer on anticoagulation. A cohort 
study by Novacek et al. found that after a first episode 
of VTE, patients with IBD had a higher risk of recurrent 
VTE than patients without IBD (HR 2.5, 95% CI 1.4–4.2; 
P = 0.001)74. There is a paucity of evidence regarding the 
efficacy and safety of thromboprophylaxis in patients 
with active IBD in the ambulatory setting, and this issue 
should be considered on a case-by-case basis.
Statement 6: Thromboprophylaxis does not increase the 
risk of further IBD-related gastrointestinal bleeding in 
patients with active disease. 
•	Consensus reached for 100%. Vote: fully agree 41%, 
mostly agree 59%.
•	 Evidence Level 2+.
Despite current recommendations, physicians are fre-
quently concerned about the safety of thromboprophy-
laxis in patients with IBD, especially those presenting 
with overt gastrointestinal bleeding due to intestinal 
inflammation. This issue has been highlighted by a 
retro spective cohort study that included 22,499 patients 
(474 with IBD), in which patients with IBD were less 
likely to receive thromboprophylaxis (79% with IBD 
versus 87% without IBD, P < 0.01), particularly if hae-
matochezia was present (OR 0.27, 95% CI 0.16–0.46)75. 
Accumulating evidence shows that thromboprophylaxis 
is safe in patients with IBD. A meta-analysis from 2007 
evaluating the efficacy and safety of adjuvant heparin in 
active ulcerative colitis concluded that it was not asso-
ciated with an increased risk of adverse events76. A retro-
spective study that included 974 patients hospitalized 
for IBD showed that the incidences of major and minor 
bleeding were similar between hospitalized patients with 
IBD who did and did not receive thromboprophylaxis77; 
also VTE prophylaxis was not associated with major 
postoperative bleeding (0.4% versus 0%, P = 0.96)77. 
A single-centre retrospective study found that in 
233 patients with IBD hospitalized due to disease 
flare-up, thromboprophylaxis was associated with a 
lower odds of overall bleeding events (OR 0.19, 95% CI 
0.14–0.26; P < 0.001), and there were no significant dif-
ferences in haemoglobin levels compared with patients 
not on chemical thromboprophylaxis (P = 0.64)78. 
Importantly, in a study by Faye et al., thromboprophy-
laxis was not associated with increased blood transfusion 
requirements (14% versus 15%; P = 0.78) or with clin-
ically significant decline in haemoglobin levels during 
hospitalization (P = 0.25)75.
Nevertheless, prophylactic anticoagulation can be 
associated with further bleeding from other sites or 
even from the gastrointestinal tract in lesions unre-
lated to IBD (such as peptic ulcer disease, or bleeding 
tumours). The overall bleeding risk should be assessed 
prior to initiation of thromboprophylaxis using either 
clinical judgement or RAM. A validated RAM for this 
purpose is the IMPROVE bleeding risk score that helps 
identify acutely ill inpatients with an increased risk of 
bleeding79–81, in whom the risk–benefit ratio of a phar-
macological thromboprophylaxis might be unfavour-
able. Notably, the IMPROVE score was developed in a 
general medical inpatient population and might not be 
necessarily be suitable for use in the IBD population. 
In patients with increased bleeding risk or contraindica-
tions to pharmacological thromboprophylaxis, mechan-
ical prophylaxis (especially intermittent pneumatic 
compression) is preferred over no treatment32,42,58.
Statement 7: IBD is associated with a small but signifi-
cant increased risk of arterial thrombotic events, espe-
cially in young patients with active disease. 
•	Consensus reached for 100%. Vote: fully agree 41%, 
mostly agree 59%.
•	 Evidence level 2++.
Atherosclerosis in several arterial beds can lead to 
thrombotic events, and systemic inflammation is a 
known risk factor for these events82. Patients with IBD 
have a slightly increased risk of arterial thrombotic 
events, even though traditional risk factors for cardio-
vascular atherosclerotic disease (CVD), such as diabetes, 
Box 2 | Risk factors for venous thrombotic events
Major risk factors
•	Active malignancy
•	recent (within 3 months) surgery with general 
anaesthesia for >30 min
•	Trauma of lower limbs
•	High-risk thrombophilia (for example, antiphospholipid 
syndrome, antithrombin deficiency)
•	Immobilization (confinement to bed in hospital with 
bathroom privileges for an acute medical condition  
for >3 days)
Minor risk factors
•	recent (within 3 months) surgery with general 
anaesthesia for <30 min
•	venous catheter
•	older age (>65 years)
•	Pregnancy and post-partum period (2 months  
after delivery)
•	oral contraceptives containing oestrogens
•	Hormone-replacement therapy
•	lower-risk thrombophilia (for example, factor v leiden 
polymorphism, prothrombin gene mutation)
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smoking, hyperlipidaemia, obesity and hypertension, are 
not universally over-represented in patients with IBD. 
In young patients, smoking, obesity and hypertension 
can explain most arterial thromboses because their 
attribut able risks are high83. In a historical cohort study, 
Aggarwal et al. included 131 patients with IBD diagnosed 
with coronary artery disease (CAD) by cardiac catheteri-
zation and matched them with 524 controls without IBD 
with CAD84. Patients with IBD were younger (65.3 ± 10.0 
versus 67.8 ± 11.0 years; P = 0.016), had a lower preva-
lence of active smoking status (10.7% versus 18.7%; 
P = 0.03) and had a lower BMI (28.0 ± 5.1 kg/m2 versus 
29.4 ± 6.4 kg/m2; P = 0.026) compared with controls84.
In a meta-analysis from 2014, Fumery et al. summa-
rized data from nine observational studies evaluating the 
risk of arterial thrombotic events in patients with IBD, 
including stroke, peripheral artery disease (PAD), mesen-
teric ischaemia and ischaemic heart disease (IHD)19. They 
found an overall increased risk of these events in ambu-
latory patients with IBD (RR 1.28, 95% CI 1.16–1.42), 
although the difference did not reach statistical 
significance when including studies with both ambula-
tory and hospitalized patients (RR 1.15, 95% CI 0.91–
1.45)19. In a population-based study from Copenhagen 
County that included 108,789 participants (of whom 
1,203 had IBD), Aarestrup et al. found that patients 
with IBD had a higher prevalence of CVD than indi-
viduals in the general population (13.2% versus 10.9%; 
P = 0.009)85. Importantly, traditional cardiovascular risk 
factors were not increased in patients with IBD and they 
actually had lower total and LDL cholesterol and blood 
pressure levels. On the other hand, patients with IBD 
had higher levels of CRP and fibrinogen as markers of 
chronic systemic inflammation, which could be the main 
driver of the increased risk of CVD in these patients85. In 
another Danish cohort study, Kristensen et al. found that 
patients with IBD had an overall increased risk of myo-
cardial infarction (RR 1.17, 95% CI 1.05–1.31), stroke 
(RR 1.15, 95% CI 1.04–1.27) and cardiovascular death 
(RR 1.35, 95% CI 1.25–1.45)86. During periods of disease 
activity these risks increased even more86.
In a French population-based study, Kirchgesner 
et al. found a statistically significant increase in the risk 
of acute arterial thrombotic events (IHD, PAD and cere-
brovascular disease; mesenteric ischaemia was excluded) 
compared with that in the general population (standard-
ized incidence rate (SIR) 1.19; 95% CI 1.16–1.22)87. The 
risk was higher in patients with Crohn’s disease than in 
patients with ulcerative colitis (SIR 1.35, 95% CI 1.30–1.41 
versus SIR 1.10, 95% CI 1.06–1.13, respectively). Periods 
of active disease (defined as 3-month periods before and 
after IBD-related hospitalization or surgery) were inde-
pendently associated with an increased risk of arterial 
events in both patients with Crohn’s disease (HR 1.74, 
95% CI 1.44–2.09) and patients with ulcerative colitis (HR 
1.87, 95% CI 1.58–2.22)87. A nested case–control study 
from France also found that diabetes (OR 14.5, 95% CI 
1.1–184.7) and clinical disease activity (OR 10.4, 95% 
CI 2.1–49.9) were independently associated with acute 
arterial thrombotic events in patients with IBD88.
A cohort study of 31,175 patients with IBD and 
154,412 matched controls without IBD found an 
increased hazard of myocardial infarction in ambula-
tory patients during periods of acute disease activity (HR 
1.83, 95% CI 1.28–2.62) and chronic disease activity 
(HR 1.69, 95% CI 1.24–2.30)89. However, patients with 
IBD do not seem to have an increased risk of cardiovas-
cular mortality. In a meta-analysis published in 2018, 
Sun and Tian found pooled standardized mortality ratios 
of 1.01 (95% CI 0.90–1.14) for patients with Crohn’s 
disease and 0.93 (95% CI 0.86–1.01) for patients with 
ulcerative colitis with low heterogeneity across studies90.
Statement 8: The risk of cerebrovascular accidents and 
ischaemic heart disease seems to be increased in female 
patients with IBD, but not in male patients. 
•	Consensus reached for 94%. Vote: fully agree 25%, 
mostly agree 69%.
•	 Evidence level 2++.
In a meta-analysis from 2014, Singh et al. found a slightly 
increased risk (adjusted OR 1.18, 95% CI 1.09–1.27) 
of cerebrovascular accident (CVA) in patients with IBD. 
Table 2 | Core recommendations




Patients with IBD should be screened for 
VTE risk factors (note: patients should not 
be routinely screened for genetic inherited 
thrombophilia)
D Statement 2
Thromboprophylaxis should be given to 
patients with IBD during hospitalization 
of any cause and maintained during the 
inpatient period
C Statement 4
Extended-duration prophylaxis after 
discharge should be considered only in 
patients with strong risk factors for VTE
D Statement 4
Thromboprophylaxis should be considered 
in ambulatory patients with active IBD with 
known risk factors for VTE
D Statement 5
Disease activity should be resolved to reduce 
the risk of thrombotic events; deep remission 
should be the target
D Statement 11
Established cardiovascular disease risk 
factors should be actively investigated and 
controlled in patients with IBD
C Statement 12
Smoking cessation should be encouraged B Statement 12
Folate supplementation should be advised in 
patients with IBD on methotrexate to avoid 
hyperhomocysteinaemia
C Statement 13
Steroid exposure should be limited to prevent 
venous and arterial thrombotic events
B Statement 15
Tofacitinib 10 mg BID should be used as 
induction therapy for up to 16 weeks; 
tofacitinib 5 mg BID should be the preferred 
maintenance dose; in patients with an 
insufficient response to the maintenance dose, 
dose increase to 10 mg BID could be considered 
in patients without known risk factors of VTE 
and without therapeutic alternatives
B Statement 18
BID, twice daily; IBD, inflammatory bowel disease; VTE, venous thromboembolism. aAccording 
to the SIGN grading system (Supplementary Table 2).
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Importantly, the risk of CVA was significantly higher in 
female patients (adjusted OR 1.28, 95% CI 1.17–1.41) 
but not in male patients (adjusted OR 1.11, 95% CI 
0.98–1.25) with IBD (P = 0.05)91. Additionally, the 
magnitude of increased CVA risk was higher in young 
patients (<40–50 years) with IBD (adjusted OR 1.84, 
95% CI 1.28–2.66) than in older patients with IBD 
(adjusted OR 1.11, 95% CI 1.02–1.21). Older patients 
usually have less severe disease with a milder course 
of IBD than younger patients; thus, the increased risk of 
these events seen in younger patients could be explained 
by higher disease activity. Also, with increasing age, tra-
ditional cardiovascular risk factors become more prev-
alent, which might outweigh the risk from milder IBD 
seen in the older population.
The meta-analysis by Fumery et al. did not find dif-
ferences in the risk of IHD in patients with IBD (RR 
1.23, 95% CI 0.94–1.62)19. However, in the meta-analysis 
by Singh et al., which included six studies, the risk of 
this event was slightly increased (adjusted OR 1.18, 
95% CI 1.08–1.31)91. As seen with the risk of CVA, the 
increased risk of IHD in patients with IBD was seen in 
female patients (adjusted OR 1.26, 95% CI 1.18–1.35), 
but not in male patients (adjusted OR 1.05, 95% CI 
0.92–1.21). Sex differences in the risk of CVA and IHD 
in patients with IBD might be explained by a greater role 
of systemic inflammation and hormonal differences in 
female patients92. Additionally, the higher background 
risk in male patients of these events might outweigh the 
increased risk attributed to IBD. The increased risk of 
IHD has also been shown in an updated meta-analysis 
by Feng et al. (adjusted RR 1.24, 95% CI 1.14–1.35)93. 
Again, in a subgroup analysis, the risk of IHD was 
more pronounced among female patients (adjusted RR 
1.351, 95% CI 1.206–1.513) than among male patients 
(adjusted RR 1.189, 95% CI 1.028–1.375)93.
Statement 9: The risk of peripheral artery disease is 
modestly increased, especially in young patients with 
Crohn’s disease. 
•	Consensus reached for 87%. Vote: fully agree 40%, 
mostly agree 47%.
•	 Evidence level 2+.
Two meta-analyses did not show an increased 
risk of PAD in patients with IBD, but both meta- 
analyses included only two studies19,91. In a nation-
wide population-based cohort study from Taiwan 
(11,067 patients with IBD; 43,765 age, sex and 
comorbidity-matched controls), Lin et al. found that the 
risk of PAD was increased in patients with IBD (adjusted 
HR 1.24, 95% CI 1.22–1.37; adjusted for age, sex and 
comorbidities)94. Interestingly, in patients with more 
than two annual IBD-related medical hospitalizations, 
the risk of developing PAD was the highest (adjusted HR 
27.5, 95% CI 18.7–40.4), showing a possible association 
with disease activity94.
In a more recent French cohort study by Kirchgesner 
et al., the risk of PAD was significantly increased in patients 
with IBD compared with the risk in the general popula-
tion (SIR 1.27, 95% CI 1.17–1.37). This risk was signifi-
cantly higher in patients with Crohn’s disease (SIR 1.65, 
95% CI 1.46–1.83), but not in those with ulcerative colitis 
(SIR 1.07, 95% CI 0.96–1.18)87. In patients with Crohn’s 
disease, the relative risk of PAD was the highest in those 
younger than 35 years (SIR 3.04, 95% CI 1.45–4.63) and 
this risk decreased successively with increasing age, 
becoming non-significant in those older than 75 years.
Statement 10: The risk of mesenteric ischaemia is 
increased in patients with IBD, especially in young 
patients with ulcerative colitis. 
•	Consensus reached for 93%. Vote: fully agree 33%, 
mostly agree 60%.
•	 Evidence level 2+.
Factors, such as local leukocyte infiltration and 
cytokine production, might interact with systemic 
inflammation, potentially leading to a particularly 
increased risk of this arterial event in patients with 
IBD95,96. The meta-analysis by Fumery et al. examined 
the risk of mesenteric ischaemia in patients with IBD. 
They included only two studies, and found a significant 
increased risk of this event in patients with IBD (RR 
3.46, 95% CI 1.78–6.71)19. In a large nationwide cohort 
study from Taiwan, which included 9,363 patients with 
IBD and 37,452 matched controls without IBD, the 
long-term risk of mesenteric ischaemia was significantly 
higher in patients with IBD than in controls, with the 
risk of mesenteric ischaemia within 13 years more than 
sixfold higher (adjusted HR 6.33, 95% CI 4.75–8.43)97. 
The magnitude of the risk of mesenteric ischaemia also 
seems to be associated with younger age, with the risk 
almost 50-fold higher in patients with IBD younger than 
45 years than in individuals without IBD (adjusted HR 
48.2, 95% CI 11.4–205.0). Additionally, patients with 
ulcerative colitis have approximately twice the risk of 
mesenteric ischaemia compared with patients with 
Crohn’s disease (adjusted HR 2.07, 95% CI 1.41–3.03)97.
Statement 11: Control of disease activity is an important 
factor in reducing the risk of venous and arterial throm-
botic events in patients with IBD. 
•	Consensus reached for 93%. Vote: fully agree 40%, 
mostly agree 53%.
•	 Evidence level 4.
Moderate to severe IBD activity has been identified 
as a risk factor for both VTE (see Statements 3 and 5) 
and arterial thrombotic events (see Statement 7). Disease 
activity should be regarded as a modifiable risk factor 
for these events, and aggressive control of inflammation 
might reduce the risk of thrombosis in patients with 
IBD. Physicians should aim for combined clinical and 
endoscopic remission, given that persistent subclinical 
inflammation can also increase the risk of events. In the 
general population, elevation of inflammatory markers, 
particularly CRP, is associated with an increased risk of 
IHD9. IBD therapies have the potential to reduce these 
risks by halting inflammation and, therefore, to reduce 
the risk of thrombotic events. However, some IBD ther-
apies might have an intrinsic pro-thrombotic effect that 
could tilt the balance towards an increased risk of venous 
and/or arterial events (see Statements 13 to 19).
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Statement 12: Established cardiovascular disease risk 
factors should be actively investigated and controlled in 
patients with IBD. 
•	Consensus reached for 100%. Vote: fully agree 73%, 
mostly agree 27%.
•	 Evidence level 4.
Patients with IBD should be screened for CVD risk 
factors, as atherosclerosis is responsible for most arterial 
thrombotic events. Several factors are associated with an 
increased risk of atherosclerotic plaques in multiple arterial 
beds (coronary, cerebrovascular, peripheral, mesenteric). 
Traditional CVD risk factors include hypertension, diabe-
tes, hyperlipidaemia, smoking and obesity. Additionally, 
risk-enhancing factors can further modify the CVD risk 
and can influence the need for primary prevention ther-
apies. They include family history of premature athero-
sclerotic CVD, familial hypercholesterolaemia, metabolic 
syndrome, chronic kidney disease, chronic inflamma-
tory conditions, history of premature menopause or 
pregnancy-associated conditions, ethnicities or races at 
high risk (such as South Asian ancestry), lipid abnormali-
ties (including hypertriglyceridaemia or elevated lipopro-
tein(a) or apoB), and elevated CRP level98. Other biological 
risk factors for CVD include hyperhomocysteinaemia99 
owing to vitamin deficiencies in relation to altered 
absorption100 and antiphospholipid antibodies either pri-
mary or mediated by a concomitant autoimmune disease 
(for example, systemic lupus erythematosus), or chronic 
inflammation36. These biological risk factors increase the 
risk of developing both arterial and venous thromboses.
CVD risk factors are not universally over-represented 
in patients with IBD (see Statement 7). Additionally, 
treatments (particularly steroids) prescribed for flares 
as well as the inflammatory nature of IBD itself can also 
increase CVD risk101,102.
Several models and calculators for CVD risk assess-
ment that take into account these risk factors have been 
developed98,103–105, but these are beyond the scope of this 
paper. However, these tools fail to reliably identify patients 
<40 years of age at high risk83,104. Patients with IBD should 
be advised not to smoke and to follow a healthy lifestyle 
to avoid obesity. Smoking cessation should be strongly 
advised: smoking is a known risk factor for arterial and 
venous events per se106,107, and can also increase the risk 
of these events further through disease activity, given 
that smoking is associated with more aggressive disease, 
especially in Crohn’s disease108. Smoking, hypertension 
and hypercholesterolaemia should be systematically 
screened for according to age-specific guidelines for 
the general population. Owing to a higher risk of CVD, 
selected patients with IBD (such as those older than 
40 years or younger patients with known risk factors) 
should be referred to general practitioner and/or cardio-
logist or vascular medicine specialist for screening for 
and control of CVD risk factors.
Regarding antiplatelet therapy, it is recom-
mended that all patients with a history of an arterial 
atherosclerosis-related thrombosis event should be 
prescribed long-term low-dose aspirin for secondary 
prevention109. Low-dose aspirin in primary prevention 
has been extensively studied and is still controversial 
even in high-risk populations due to an unfavourable 
benefit–risk ratio110–113. This issue is particularly true in 
older patients >70 years of age who have a high risk of 
bleeding114. Since the increasing prescription of statins 
during the past few decades to reduce the risk of a first 
CVD event due to plaque rupture, the beneficial effect 
of aspirin has been challenged114. Thus, in primary pre-
vention, low-dose aspirin should be discouraged in older 
patients >70 years of age and can be considered in 
young patients with a high CVD risk who still have 
uncontrolled CVD risk factors despite conventional treat-
ments (such as statins or antihypertensive drugs)98. In 
patients with IBD, the use of aspirin seems to be safe and 
is not related to worse disease outcomes. In a retrospective 
study in 2021 that included 764 patients with IBD, aspirin 
use was not associated with IBD-related hospitalization, 
corticosteroid use, or IBD-related surgery115.
Risk of drug-related thrombosis in patients  
with IBD
Statement 13: There is limited evidence regarding 
the effect on the risk of VTE with the use of 5-ASA, 
thiopurines or methotrexate in patients with IBD. 
•	Consensus reached for 100%. Vote: fully agree 47%, 
mostly agree 53%.
•	 Evidence level 3.
There is a paucity of evidence regarding the potential 
effect of 5-aminosalicylic acid (5-ASA) compounds on 
the risk of VTE. A small study showed that, independ-
ent of diagnosis or disease activity, spontaneous ex-vivo 
platelet activation was 50% lower in patients with IBD 
taking 5-ASA orally than in those not on such treatment 
(P < 0.05)116. In vitro, 5-ASA significantly reduced both 
spontaneous (P < 0.03) and thrombin-induced platelet acti-
vation (P < 0.02)116. These observations could lead to the 
assumption that 5-ASA could theoretically reduce the risk 
of VTE. On the other hand, a previous small study in six 
patients with IBD (four with ulcerative colitis, and two with 
Crohn’s disease) treated with 5-ASA showed no changes 
in platelet aggregation or fibrinolytic activity117. These 
are small limited studies, and clinical evidence regarding 
the risk of VTE in patients with IBD on 5-ASA is lacking. 
However, data from RCTs investigating the use of mesala-
zine in patients with ulcerative colitis have not shown any 
safety signal towards an increased risk of VTE118.
Indirect data suggest a potential antithrombotic effect 
from thiopurines. One study showed that azathioprine 
inhibits in vitro platelet aggregation119. Additionally, 
another study showed that patients with IBD on thio-
purines had fewer leukocyte–platelet aggregates than 
patients who were not on thiopurines120. As with 5-ASA, 
there is paucity of clinical data showing a reduced risk of 
thrombotic events with the use of thiopurines in patients 
with IBD, and accumulated evidence does not show an 
increased risk of VTE with immunomodulators. For 
example, in a prospective cohort study that included 
245 patients with IBD exposed to thiopurines with a 
median follow-up of 32 months (range 0.2–75 months), 
no VTE event was reported121.
Methotrexate can increase the levels of homocysteine 
in the absence of folate supplementation, which may 
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potentially increase the risk of VTE122,123. This could 
be particularly relevant given that patients with IBD 
have an increased risk of hyperhomocysteinaemia124. 
A meta-analysis from 2011 summarized data from 
28 studies and found that risk of hyperhomocysteinae-
mia was significantly higher in patients with IBD when 
compared with controls (OR 4.65, 95% CI 3.04–7.09)124. 
However, its effect on the risk of thrombosis in patients 
with IBD is less clear, as the odds of having hyper-
homocysteinaemia was not increased among patients 
who experienced thrombotic complications (OR 1.97, 
95% CI 0.83–4.67)124. In patients with rheumatoid arth-
ritis taking methotrexate, folate supplementation was 
associated with normalization of homocysteine levels123. 
Folate supplementation should be advised to avoid 
hyperhomocysteinaemia in patients with IBD. A retro-
spective cohort study of 782 patients with IBD starting 
thiopurines or methotrexate found that 27% disconti-
nued therapy owing to adverse events (40% on metho-
trexate versus 19% on thiopurines, P < 0.001), but none 
discontinued therapy owing to thrombotic events125.
Statement 14: 5-ASA is associated with a reduced risk of 
ischaemic heart disease in patients with IBD, especially 
when given in the long term. 
•	Consensus reached for 100%. Vote: fully agree 36%, 
mostly agree 64%.
•	 Evidence level 2−.
A nationwide population-based cohort study from 
Denmark by Rungoe et al. included 4,570,820 individu-
als, of whom 28,833 were diagnosed with IBD (7,521 
with Crohn’s disease, 19,990 with ulcerative colitis)126. 
During up to 13 years of follow-up, 245,019 incident 
cases of IHD were identified, of which 1,175 occurred 
among patients with IBD. Patients with IBD had a signif-
icantly increased risk of IHD (incidence rate ratio (IRR) 
1.59, 95% CI 1.50–1.69) compared with those without 
IBD126. Importantly, 5-ASA users had a lower risk of IHD 
than those who did not use 5-ASA (IRR 1.16 versus 1.36; 
P = 0.02), even after adjustment for corticosteroid use as 
a proxy for disease severity. In long-term users of 5-ASA 
(defined as those with three or more redeemed prescrip-
tions), the risk was even lower (IRR 1.08, 95% CI 0.98–
1.19) and was non-significant compared with individuals 
without IBD126. A cardioprotective effect of 5-ASA could 
be explained by salicylic acid being the main active frac-
tion of 5-ASA as well as of aspirin. However, a causal rela-
tionship cannot be fully established from these results, 
given that population-based studies do not allow ade-
quate discrimination between 5-ASA use, disease activ-
ity and IHD. Further studies are needed to confirm the 
cardioprotective effect of 5-ASA, and currently there is 
insufficient evidence to recommend the use of 5-ASA in 
patients with IBD solely to prevent arterial events.
Statement 15: Steroids are associated with an increased 
risk of venous and arterial thrombotic events in patients 
with IBD. 
•	Consensus reached for 100%. Vote: fully agree 31%, 
mostly agree 69%.
•	 Evidence level 2++.
In a retrospective study, Higgins et al. included 
15,100 patients with IBD and identified 335 VTE events 
during the period 2003–2009 (reF.127). The absolute rates 
of VTE within 12 months after an index prescription 
were 2.25% (296 of 13,165), 0.44% (2 of 452), and 2.49% 
(37 of 1,483) for patients exposed to corticosteroid only, 
biologic agent only, and combination of corticosteroid 
plus a biologic agent, respectively. When compared with 
corticosteroid monotherapy, monotherapy with a biol-
ogic agent was associated with an adjusted OR of 0.21 
(95% CI 0.05–0.87) for VTE, whereas for combinations 
of corticosteroids plus a biologic agent the adjusted 
OR was 1.01 (95% CI 0.71–1.45)127. Importantly, after 
controlling for covariates, the use of high-dose corti-
costeroids was associated with an OR of 3.31 (95% CI, 
2.50–4.37) compared with low-dose corticosteroids, 
indicating a dose–response effect on the risk of VTE. 
The authors also evaluated the risk of VTE over time; 
they found no additional VTE events after 2 months in 
patients receiving monotherapy with a biologic agent, 
whereas in those receiving corticosteroids (mono-
therapy or combined with a biologic agent), VTE 
events continued to occur during up to 12 months of 
follow-up127.
In a retrospective cohort study from the Veterans 
Health Administration including 30,456 patients with 
IBD128, the incidence rate of VTE increased after the 
diagnosis of IBD, although this increase was more pro-
nounced in patients exposed to corticosteroids than in 
patients not exposed (3.1 to 9.0 per 1,000 person-years 
versus 2.1 to 4.9 per 1,000 person-years). In patients 
exposed to corticosteroids the rate of VTE increased 
more than fivefold (16.9 per 1,000 person-years) 
in the year after corticosteroid exposure compared 
with the year prior to diagnosis128.
In a meta-analysis published in 2018, six studies were 
included assessing the risk of VTE in patients with IBD 
treated or not with systemic corticosteroids129. A total 
of 40,083 patients with IBD were analysed and 2,861 
(7.13%) VTE events were identified. There was a signif-
icantly higher rate of VTE in patients treated with cor-
ticosteroids than in patients without steroid medication 
(OR 2.20, 95% CI 1.70–2.86; P < 0.001)129.
Systemic corticosteroids seem to be also associated 
with an increased risk of arterial thrombotic events, 
as seen in other immune-mediated diseases and in 
the general population130,131. In a nested case–control 
study, Andersohn et al.132 found that patients with 
Crohn’s disease who had a CVA were more likely to 
have received a corticosteroid prescription in the 
preceding 3 months than patients who did not have a 
CVA (adjusted OR 1.71, 95% CI 1.34–2.19). In the 
aforementioned population-based study by Rungoe 
et al., patients who required oral corticosteroids had 
a significantly higher risk of IHD (IRR 1.37, 95% CI 
1.25–1.50) than patients who had never received 
oral corticosteroids (IRR 1.23, 95% CI 1.12–1.36; 
P < 0.01)126. However, it should be noted that corti-
costeroid use can be regarded as a proxy for disease 
activity, and the latter is a known risk factor for arterial 
events (see Statement 7); hence a causal relationship 
cannot be fully established.
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Statement 16: Anti-TNF agents can be associated with a 
decreased risk of VTE in patients with IBD. 
•	Consensus reached for 100%. Vote: fully agree 41%, 
mostly agree 59%.
•	 Evidence level 2+.
TNF has been implicated in accelerated thrombus 
formation and activation of coagulation6, so anti-TNF 
agents might have a potential protective effect against 
VTE, besides their intrinsic efficacy in reducing 
disease activity.
A prospective study included 103 patients with 
IBD starting infliximab and 113 healthy individuals as 
controls found that patients with IBD have increased 
concentrations of active inhibitors of the fibrinolytic 
system, which might be involved in the increased risk of 
thrombotic events. Interestingly, patients who responded 
to infliximab therapy had a normalization of their clot 
lysis profile133. These results were confirmed in a more 
recent study supporting the notion that anti-TNF agents 
reduce the risk of VTE134.
In a retrospective cohort study of 547 hospitalized 
patients with IBD, systemic corticosteroid use (OR 4.62, 
95% CI 1.98–10.80) was associated with an increased 
risk of VTE, whereas anti-TNF agents were associated 
with a reduced risk (OR 0.20, 95% CI 0.04–0.99)135. 
A cohort study that included 5,173 patients with 
IBD, evaluated the risk of VTE in patients exposed to 
anti-TNF agents and in those exposed to non-biologic 
drugs (thiopurines, methotrexate or ciclosporin)136. The 
authors did not find a statistically significant difference 
between the groups in the overall population (adjusted 
HR 0.78, 95% CI 0.60–1.02), although in patients with 
Crohn’s disease (HR 0.62, 95% CI 0.44–0.86) and those 
younger than 45 years (HR 0.55, 95% CI 0.34–0.87) a 
protective effect of anti-TNF agents reached statis-
tical significance136. A meta-analysis by Sarlos et al. 
included three studies that compared the risk of VTE 
in patients with IBD treated with anti-TNF agents ver-
sus systemic corticosteroids, including 18,435 patients 
with 399 (2.2%) VTE events. A significantly lower rate 
of VTE events was seen in patients with IBD treated 
with anti-TNF agents than those treated with steroids 
(OR 0.27, 95% CI 0.11–0.67)129.
In a prospective cohort study evaluating the 
long-term safety outcomes of infliximab treatment, 
a higher incidence of VTE was seen in patients on 
anti-TNF agents (0.16 events per 100 patient-years) 
than in patients on other treatments, such as thiopurines 
or methotrexate (0.10 events per 100 person-years)137. 
However, these estimates were not adjusted for disease 
severity and other covariates. There are no consistent 
safety signals of an increased risk of VTE in patients with 
IBD treated with vedolizumab or ustekinumab. A study 
by Cross et al. found that patients with Crohn’s disease 
exposed to vedolizumab had an increased incidence of 
PE (IRR 3.01, 95% CI 1.11–8.18) and DVT (IRR 2.67, 
95% CI 1.32–5.41) compared with those exposed to 
anti-TNF agents138. These findings should be interpreted 
with caution given the small absolute number of VTE 
events in patients on vedolizumab (n = 12) and also the 
fact that patients exposed to vedolizumab had higher 
corticosteroid use (78.8% versus 48.9%). Additionally, 
RCTs and large real-world studies have not reported 
VTE events139–141. There is a paucity of studies evaluating 
the risk of VTE with the use of ustekinumab in the IBD 
population. In the Psoriasis Longitudinal Assessment 
and Registry (PSOLAR) study, in which 12,093 patients 
with psoriasis were enrolled (40,388 patient-years of 
follow-up), there were no reports of VTE in patients 
exposed to ustekinumab (40,388 patient-years of 
follow-up)142.
Statement 17: Anti-TNF agents can be associated with 
a reduced risk of arterial events in patients with IBD. 
•	Consensus reached for 94%. Vote: fully agree 29%, 
mostly agree 65%.
•	 Evidence level 2+.
In a retrospective cohort study, Lewis et al.143 found 
that among patients with Crohn’s disease (7,694 with 
prolonged corticosteroid use and 1,879 with anti-TNF 
agent use) the risk of death was statistically significantly 
lower in patients treated with anti-TNF therapy than in 
patients on corticosteroids (OR 0.78, 95% CI 0.65–0.93) 
and also anti-TNF therapy was associated with lower 
rates of major adverse cardiovascular events (MACE) 
(OR 0.68, 95% CI 0.55–0.85).
In a 2020 nationwide population-based cohort 
study from France including 177,827 patients with IBD, 
Kirchgesner et al. analysed the effect of thiopurines 
and anti-TNF agents on the risk of acute arterial events 
(IHD, CVA and PAD)144. Patients exposed to anti-TNF 
agents had a lower risk of acute arterial events than 
patients without exposure to anti-TNF agents or thio-
purines (HR 0.79, 95% CI 0.66–0.95). The magnitude 
of the risk reduction was highest in men with Crohn’s 
disease exposed to anti-TNF agents (HR 0.54, 95% CI 
0.40–0.72). Notably, in patients exposed to thiopurines 
the risk was not significantly changed. A meta-analysis 
that included 24 studies found that exposure to biologic 
agents in patients with an IMID was associated with 
a 30% lower odds of cardiovascular events (OR 0.70, 
95% CI 0.59–0.82)145.
There is paucity of data regarding the risk of arterial 
events with the use of newer biologic agents (that is, ved-
olizumab and ustekinumab) in patients with IBD. Data 
from clinical trials and post-marketing safety reports 
do not show any safety signal towards an increased risk 
of venous or arterial events in patients with IBD146,147. 
Regarding ustekinumab, a meta-analysis evaluated 
the risk of MACE in patients with psoriasis receiving 
biologic agents (eight RCTs involving 3,862 patients) 
and found no significant increased risk of MACE in 
patients exposed to ustekinumab (OR 4.48, 95% CI 
0.24–84.77)148. However, a 2020 case–time–control study 
suggested that the initiation of treatment with usteki-
numab is associated with an increased risk of severe 
arterial events (acute coronary syndrome or stroke) 
in patients with a high baseline cardiovascular risk149. 
The majority of patients had psoriasis (91%) with only 
6% having Crohn’s disease149. This observation needs 
to be confirmed in further studies, and its relevance in 
patients with IBD remains unclear.
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Statement 18: Tofacitinib can be associated with a 
dose-dependent increased risk of VTE in patients 
with rheumatoid arthritis with risk factors for VTE. 
According to available evidence, no increase in the risk 
of VTE has been observed in the overall ulcerative colitis 
population treated with tofacitinib. 
•	Consensus reached for 100%. Vote: fully agree 50%, 
mostly agree 50%.
•	 Evidence level 1+.
In a recently completed, open-label, post-marketing 
study, the safety of tofacitinib versus an anti-TNF agent 
was evaluated. Patients with moderate to severe rheu-
matoid arthritis refractory to methotrexate, older than 
50 years, and with at least one cardiovascular risk fac-
tor were enrolled (ORAL Surveillance Study; study 
A3921133, NCT02092467). Analysis in February 2019 
showed statistically and clinically important differences 
in the occurrence of PE (HR 5.96, 95% CI 1.75–20.33) 
and mortality (HR 3.28, 95% CI 1.55–6.95) between 
patients receiving tofacitinib 10 mg twice daily (BID) 
and those receiving the anti-TNF agent. Importantly, 
the incidence rates of PE and mortality among patients 
receiving tofacitinib 10 mg BID were higher in those 
with background risk factors for VTE than in patients 
without them. Based on these results, both the FDA and 
EMA have released a warning150,151, and the FDA has 
limited the use of tofacitinib to patients with ulcerative 
colitis that are refractory or intolerant to treatment with 
anti-TNF agents. The mechanism involved in the poten-
tial increased risk of VTE associated with tofacitinib is 
poorly understood.
In a large cohort study by Desai et al. in 50,865 
patients with rheumatoid arthritis starting treatment 
with tofacitinib or anti-TNF agents, a numerically, but 
statistically non-significantly, higher risk of VTE was 
seen in patients receiving tofacitinib (unadjusted HR 
1.42, 95% CI 0.84–2.40)152. Notably, a greater propor-
tion of patients starting tofacitinib were receiving more 
than three non-biologic disease-modifying antirheu-
matic drugs and corticosteroids at baseline, probably 
indicating more severe disease or a longer duration of 
the active systemic inflammation152. A meta-analysis 
published in 2020 that included ten controlled studies 
and 5,143 patients exposed to JAK inhibitors did not find 
significant differences in the risk of VTE with the use of 
JAK inhibitors in patients with an IMID (RR 0.90, 95% 
CI 0.32–2.54)153.
A post hoc analysis evaluated the occurrence DVT 
and PE in the tofacitinib development programme 
in ulcerative colitis, from the induction and mainte-
nance studies and from the open-label extension (OLE) 
study154. In this analysis, one patient developed DVT and 
four patients had PE during treatment with tofacitinib, 
out of 1,157 patients in the overall cohort. All VTE events 
in patients receiving tofacitinib at the time of the event 
occurred during the OLE study, after at least 7 months 
of treatment (tofacitinib exposure range 216–1,149 days) 
and in patients receiving 10 mg BID. All these patients 
had at least one VTE risk factor at the same time (for 
example, obesity, hormone-replacement therapy, prior 
history of VTE)154. Importantly, during the induction 
and maintenance studies, four patients developed VTE 
events; all were receiving placebo at the time of event, 
and none of the tofacitinib-exposed patients developed 
VTE events during the induction and maintenance stud-
ies of the OCTAVE programme. In the overall cohort, the 
incidence rate of PE in all patients exposed to tofacitinib 
(2,403.6 patient-years of exposure) was 0.16 per 100 
patient-years (95% CI 0.04–0.41), whereas in patients 
exposed to the predominant dose of tofacitinib 10 mg 
BID (1,808.1 patient-years of exposure) it was 0.21 per 
100 patient-years (95% CI 0.06–0.55). These incidence 
rates for VTE events with tofacitinib were comparable 
with those previously reported for patients with ulcer-
ative colitis155. Given these results, the risk of VTE does 
not seem to be increased in patients with ulcerative colitis 
exposed to tofacitinib. However, further studies in a pop-
ulation of patients with ulcerative colitis enriched with 
VTE risk factors are needed to fully determine whether 
this safety signal seen in patients with rheumatoid 
arthritis is also applicable to those with ulcerative colitis.
In a real-world cohort of 260 patients with ulcerative 
colitis exposed to tofacitinib with a median follow-up 
time of 6 months (interquartile range 2.7–11.5 months), 
VTE was identified in two patients, giving an IRR 
for VTE of 1.32 per 100 patient-years of follow-up 
(95% CI 0.33–5.28). Both patients were on tofacitinib 
10 mg BID at the time of the event and had provoking 
risk factors for VTE156.
Given that VTE has been highlighted as a potential 
risk during treatment with tofacitinib, physicians should 
acknowledge this possibility and individualize manage-
ment by screening for risk factors for VTE (Statement 2) 
prior to and during treatment with tofacitinib in patients 
with ulcerative colitis. Physicians should also aim for the 
lowest effective dose of tofacitinib. Tofacitinib 10 mg BID 
should be used as induction therapy for up to 16 weeks. 
Tofacitinib 5 mg BID should be the preferred mainte-
nance dose. In patients with insufficient response to the 
maintenance dose, a dose increase to 10 mg BID could 
be considered in patients without known risk factors for 
VTE and without therapeutic alternatives.
Statement 19: Tofacitinib is not associated with an 
increased risk of major adverse cardiovascular events in 
patients with ulcerative colitis. 
•	Consensus reached for 100%. Vote: fully agree 50%, 
mostly agree 50%.
•	 Evidence level 1−.
Tofacitinib has been associated with alterations in 
the serum lipids profile and, given that hypercholes-
terolaemia is a known risk factor for cardiovascular 
events in general population, the possible occurrence 
of MACE with the use tofacitinib has long been a con-
cern. However, changes seen in cholesterol levels are 
small and transient, with the LDL to HDL ratio usually 
stable. Additionally, these changes have been shown 
to be reversible with statin treatment in patients with 
rheumatoid arthritis157.
A post hoc analysis of the tofacitinib development 
programme in ulcerative colitis found an incidence rate 
per 100 years of exposure of 0.24 (95% CI 0.07–0.62; 
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median treatment duration 514 days; exposure 1,612.8 
patient-years)158. This finding is in line with the incidence 
rates of MACE seen with the use of anti-TNF agents in 
patients with ulcerative colitis (incidence rate 0.51, 95% 
CI 0.31–0.79)159. MACEs were reported in four patients 
exposed to tofacitinib; three of these patients had four 
or more traditional cardiovascular risk factors, including 
hyperlipidaemia, hypertension, diabetes mellitus, history 
of smoking, and/or family history of CAD160. However, 
the majority of patients in the cohort did not have 
cardio vascular risk factors at baseline, with only 6.1% of 
patients taking lipid-lowering medications at baseline158.
In a meta-analysis by Olivera et al., no significant 
increased risk of MACE was seen in patients with IBD 
exposed to JAK inhibitors, as well as in the risk of a 
myriad of IMIDs (RR 1.07, 95% CI 0.56–2.01)153. 
Another meta-analysis by Xie et al.161 including 29 RCTs 
evaluating tofacitinib in patients with IMIDs found no 
significant increase in the risk of all cardiovascular 
events (OR 1.07, 95% CI 0.49–2.34), MACE (OR 1.54, 
95% CI 0.42–5.59), or all-cause mortality (OR 1.13, 95% 
CI 0.26–4.95).
Conclusions
The ultimate goal of this consensus meeting was 
to give recommendations to improve the quality of 
care of patients with IBD and prevent potentially 
life-threatening complications of thrombosis. This 
consensus meeting led to the development of a series 
of statements (Box 1) supported by available evidence 
regarding the background risk of thrombotic events 
in patients with IBD, as well as how this risk is mod-
ulated by commonly used drug therapies in IBD (that 
is, 5-ASA, thiopurines, methotrexate, steroids, biologic 
agents and tofacitinib). Additionally, whenever appro-
priate consensus recommendations for the prevention of 
venous, arterial and drug-related thrombosis are made 
(TaBle 2). Treatment strategies of established thrombotic 
events in patients with IBD were beyond the scope of 
this consensus, and physicians should refer to available 
guidelines32.
Further evidence is needed regarding the drug-related 
risk of thrombosis with newer therapies in the IBD 
population, specifically the risk of MACE with usteki-
numab and the risk of VTE with tofacitinib and other 
JAK inhibitors. Real-world studies as well as controlled 
studies specifically designed to address this important 
issue are warranted. Development of specific risk assess-
ment tools for thrombotic complications in patients with 
IBD are needed, as they might influence management 
in some clinical scenarios (such as thromboprophylaxis 
during ambulatory flares).
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